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A Viral Phospholipase A2 Is Required
for Parvovirus Infectivity
(Takahashi et al., 1998b) remain to be confirmed (Moore,
2000).
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Cell entry by nonenveloped viruses is still not well
understood (Kasamatsu and Nakanishi, 1998). Recep-
Summary tors that have been reported for parvoviruses include
globoside for B19 (Brown et al., 1993), human fibroblast
Sequence analysis revealed phospholipase A2 (PLA2) growth factor receptor 1, heparin sulfate andV5 integ-
motifs in capsid proteins of parvoviruses. Although rin for adeno-associated virus (AAV) (Qing et al., 1999;
PLA2 activity is not known to exist in viruses, putative Summerford et al., 1999), and transferrin receptor for
PLA2s from divergent parvoviruses, human B19, por- CPV (Parker et al., 2001). Parvovirus internalization in-
cine parvovirus, and insect GmDNV (densovirus from volves dynamin-dependent receptor-mediated endocy-
Galleria mellonella), can emulate catalytic properties tosis (Parker and Parrish, 1997, 2000), followed by
of secreted PLA2. Mutations of critical amino acids slower intracellular trafficking. Treatments that block the
strongly reduce both PLA2 activity and, proportionally, early to late endosomal transport (bafilomycin A1, noco-
viral infectivity, but cell surface attachment, entry, and dazole, low temperature) also inhibited virus infection
endocytosis by PLA2-deficient virions are not affected. (Vihinen-Ranta et al., 1998; Douar et al., 2001; Hansen
PLA2 activity is critical for efficient transfer of the viral et al., 2001), suggesting that transport to the late endo-
genome from late endosomes/lysosomes to the nu- some is required for productive infection. Viral DNA is
cleus to initiate replication. These findings offer the delivered to the nucleus, either from this endocytic com-
prospect of developing PLA2 inhibitors as a new class partment or from the cytoplasm (Parker and Parrish,
of antiviral drugs against parvovirus infections and 2000); however, the molecular mechanisms that regulate
associated diseases. nuclear delivery remain unclear.
The role of VP1up in parvovirus entry is essential.
Several functions have been attributed to VP1up. VP1upIntroduction
of Aleutian Disease Virus (ADV) parvovirus has DNA
binding activity (Willwand and Kaaden, 1988), whereas inParvoviruses infect vertebrates and invertebrates and
other parvoviruses it has been shown to contain nuclearoccasionally emerge in new hosts. Newly arisen parvovi-
localization signals (Tullis et al., 1993; Vihinen-Ranta etruses may cause pandemics with high mortality rates
al., 2000). Cotmore et al. (1999) demonstrated thatas demonstrated by the sudden appearance of canine
VP1up resides, unexpectedly, within the virion of MVMparvovirus (CPV) during the late 1970s (Parrish, 1999).
and is not accessible from the outside. They showed,Parvoviruses depend on the S phase of the host cell for
however, that VP1up can be externalized from intactreplication (Berns, 1996). This predilection for dividing
particles and suggested that this occurs during viralcells is reflected in a wide tropism of the virus for fetal
entry.
tissues compared to the narrower range of cells affected
The VP1up of almost all parvoviruses contains a con-
in adult animals. The human parvovirus B19 causes ery-
served domain of about 40 amino acids of as yet un-
thema infectiosum, a childhood disease, hydrops fetalis, known function. Comparison of this domain from insect
and abortion (Brown, 2000). It has also been associated parvovirus GmDNV (densovirus from Galleria mellonella)
with different autoimmune diseases such as rheumatoid with that of porcine parvovirus (PPV) revealed about
arthritis (RA), systemic lupus erythematosus (SLE), 90% identity (Tijssen and Bergoin, 1995), while the re-
adult-onset Still’s disease, and polyarthritis (Foto et al., mainder of their VPs exhibited hardly any similarity
1993; Ytterberg, 1999). Virus-associated arthropathy is (Chapman and Rossmann, 1993; Simpson et al., 1998).
usually self-limiting and transient (Takahashi et al., Here, we show that some amino acids in the conserved
1998a). Findings that B19 initiates and perpetuates RA domain of VP1up match critical amino acids in the cata-
lytic site of secretory phospholipase A2 (sPLA2), an activ-
ity that was not known to exist in virus capsids. PLA2s3 Correspondence: peter.tijssen@inrs-iaf.uquebec.ca
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Figure 1. Sequence Alignments of Parvovirus PLA2 Motifs and sPLA2 Representatives
Parvoviral and sPLA2 sequences with GenBank accession numbers (except those not yet deposited) are separated by the common structural
numbering for group I/II sPLA2 (Renetseder et al., 1985). The Ca2 binding loop is underscored by filled squares and the catalytic residues by
filled circles. Insect parvoviruses are indicated by DNV and their host name: Gm, Galleria mellonella; Ml, Mythimna loreyi; Jc, Junonia coenia;
Pi, Pseudoplusia includens; Ds, Diatraea saccharalis; Cp, Culex pipiens; Ce, Casphalia extranea; Ad, Acheta domesticus; Pf, Periplaneta
fuliginosa; Bm, Bombyx mori. Vertebrate parvoviruses are indicated with PV. K. Rat, kilham rat; MVM, minute virus of mice; Mduck, muscovy
duck; Rh/Macaq., rhesus-macaque monkeys; AAV, adeno-assotiated virus. LuIII and H1 parvoviruses originated from tissue cultures, and B19
is a human parvovirus. sPLA2 representatives are indicated by group number: IA, Naja naja snake venom PLA2; IB, human pancreatic PLA2;
IIA, human synovial fluid PLA2; IIB, gaboon viper snake venom PLA2; IIC, rat PLA2; III, bee venom PLA2; V, human PLA2; X, human PLA2. Dark
green background (white lettering), 100% identity; light green background, at least 70% conserved among all PLA2s. Dark and light red indicate
100% identity and at least 70% conserved, respectively, among pvPLA2s. Dark and light blue indicate 100% identity and at least 70%
conserved, respectively, among sPLA2s. Yellow background indicates conserved residues in vertebrate parvoviruses [conserved amino acids:
(L, V, I), (Y, W, F), (R, K)].
form a superfamily of key enzymes involved in physio- In this study, capsids of most parvoviruses were
shown to contain this enzyme domain, and this activitylogical and pathological processes such as lipid mem-
brane metabolism, signal transduction pathways, in- was found to be required for parvovirus entry. These
findings could provide a basis to study the proposedflammation, acute hypersensitivity, and degenerative
diseases (Dennis, 1997; Kramer and Sharp, 1997; Bal- link between autoimmune disorders and parvovirus in-
fections.sinde et al., 1999). PLA2s catalyze the hydrolysis of phos-
pholipid substrates at the 2-acyl ester (sn-2) position to
release lysophospholipids and free fatty acids. Among Results
the major sPLA2 groups, pancreatic sPLA2s from verte-
brates and PLA2s from snake venoms are classified in Identification of a Phospholipase A2 Motif
and Activity in the Largest Structuralgroup I, nonpancreatic and synovial sPLA2s and sPLA2s
from crotalid and viperid venoms in group II, and bee Protein of Parvoviruses
Analysis of 34 parvovirus VP1up sequences revealedvenom and related sPLA2s in group III. Members of
groups I and II have a similar 3D structure that is different that 31 contain a conserved HDXXY motif, found in the
catalytic site of sPLA2s (Dennis, 1997). Furthermore, thefrom that of group III (Renetseder et al., 1985). In addition
to various physiological roles, sPLA2s are involved in conserved Ca2 binding loop of sPLA2s, a YXGXG motif
(Dennis, 1997), was found in these 31 VP1up sequencesthe pathogenesis of inflammation and autoimmune pro-
cesses (Pruzanski and Vadas, 1991). (Figure 1). Sequences outside the catalytic site and the
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Figure 2. PLA2 Activity of Viral and Ex-
pressed Parvoviral VP1up
(A) Thin-layer chromatography after hydroly-
sis in the mixed micelles assay of phosphati-
dylcholine substrate (PL) by expressed
pvPLA2 into fatty acid (FA) and lysophosphati-
dylcholine (LPL). This activity was analyzed
with a Molecular Dynamics PhosphorImager
[percent: fraction hydrolyzed in percent 
((FA  LPL)/(FA  PL  LPL))  100]. PLA2s
used were as follows: lanes 1, 2, and 5 (0.6
ng of PPV PLA2), lanes 3 and 4 (250 ng of B19
PLA2), lane 6 (350 ng of GmDNV PLA2), lane
7 (2,000 ng thioredoxin as negative control),
and lane 8 (15 ng bee venom PLA2). The 3C9
monoclonal antibody, which binds to the C
terminus of PPV-VP1up, reduced PPV PLA2
activity of VP1up (lane 2, 18% of original ac-
tivity after adding 200 ng of antibody) but not
of B19 (lane 4). Adding EGTA to 5 mM abol-
ished PLA2 activity (lane 5).
(B) Sequences outside the conserved pvPLA2
domain increased pvPLA2 activity of the ex-
pressed PPV VP1ups. VP1up from M1 to S174
was used throughout this work and was as-
signed the relative specific activity of 1.0. Se-
quences within this expressed peptide but
outside the PLA2 motif (dark gray) contributed
to the activity as shown by the relative spe-
cific activities.
(C) The impact of Ca2 concentration, pH, and
different substrates on the activity of pvPLA2.
Since 1 mM Ca2, 50 mM Tris-HCl, pH 8.0,
and phosphatidylcholine (PC) were used in
standard assays, these were set at 100% rel-
ative activity. PE is phosphatidylethanolam-
ine, phosphatidylinositol (PI). Samples were
measured in triplicate.
(D) PLA2 activity of untreated 0.2 g virions
(lane 1) and after dissociation (lanes 2 and 3)
and heat shock (lanes 4 and 5). Bee venom
PLA2 was included as a control at 18 ng (lanes
6 and 7), and lane 8 had a negative control.
Samples in lanes 3, 5, and 7 were treated
with anti-VP1up antibodies (200 ng). These
antibodies reduced viral but not bee venom
PLA2.
Ca2 binding loop motifs are poorly conserved between VP1up polypeptides from PPV, GmDNV, and B19 par-
voviruses were expressed as thioredoxin fusion proteinsthe putative parvoviral (pv) PLA2 group and the sPLA2
groups. in order to demonstrate pvPLA2 activity. PLA2 activity of
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Figure 3. Predicted 3D Structure of PPV/B19 pvPLA2 Domain
Sequences of PPV/B19 showed homology with the N and C termini of group III sPLA2 and with the middle part of group I/II sPLA2 (IB pancreatic
sPLA2; GenBank accession numbers in Figure 1). Helices are indicated by stretches of H. The predicted 3D model of B19/PPV PLA2 has been
obtained by homology modeling using the program MOE. Both the 3D structure of pancreatic porcine PLA2 (Group I/II in orange; PDB number
1P2P) and bee venom PLA2 (Group III in magenta; PDB number 1POC) were used for homology modeling of pvPLA2 (in the middle). Residues
L, V, I as well as residues Y, F, W were considered equivalent residues. It was assumed that disulfide bridges are not essential for the structure
since mutations of cysteine did not affect enzyme activity (Zhu et al., 1995). The 3D images were generated with the program GRASP. The
color code in the sequence matches that in the pvPLA2 structure. The green color in pvPLA2 indicates residues that are conserved with both
group I/II and group III PLA2s, orange-coded residues are conserved with group I/II, and magenta-coded are conserved with group III PLA2s.
Amino acids labeled in the pvPLA2 structure were submitted to site-directed mutagenesis.
purified VP1up was measured with the mixed micelles the phosphatidylethanolamine and -inositol substrates
assay (Manjunath et al., 1994). The thioredoxin alone were labeled only at the sn-2 position, fatty acids but
did not exhibit any PLA2 activity (Figure 2A) and served not lysophospholipids could be detected after the reac-
as a control. The catalytic efficiency (kcat/KM)app of ex- tion. In contrast, phosphatidylcholine was labeled at
pressed PPV PLA2 was (71.9  9.4)  105 M1·s1 com- both sn-1 and sn-2 positions, and both fatty acid and
pared to (1.09  0.14)  105 M1·s1 for bee venom lysophospholipid products were detected with the
sPLA2. The (kcat/KM)app of B19 and GmDNV PLA2 were PhosphorImager. These data confirmed pvPLA2 as a
(2.5  0.2)  104 and (0.4  0.03)  104 M1·s1, respec- new member of the PLA2 enzyme family.
tively. Extended regions of PPV VP1up, each containing PLA2 activity in purified virus was only detected when
the conserved pvPLA2 domain, were expressed, and PPV virions were assayed at high concentrations (	4
activity determinations indicated that sequences out- g/ml), suggesting that PLA2 domains reside inside the
side the conserved domain had a large impact on the intact capsid as shown for MVM (Cotmore et al., 1999).
catalytic efficiency of the enzyme (Figure 2B). This was confirmed since disruption of the capsid by
Monoclonal antibody (3C9; ATCC CRL-1745) specific alkali denaturation and renaturation, thereby exposing
to the C terminus of the PPV-VP1up reduced the PLA2 the VP1up, increased the PLA2 activity 50- to 100-fold,
activity of PPV, but not that of B19 (Figure 2A). sPLA2 close to levels of expressed VP1up (Figure 2D). A heat
inhibitors oleyloxyethylphosphorylcholine (OP) and ma- shock of 2 min at 70
C also released VP1up as the PLA2noalide (MA) also inhibited the VP1up PLA2 activity. The activity increased about 20–50 times (Figure 2D). PLA2MA concentration for 50% inhibition (IC50) in the radiola- activity of PPV VP1up, exposed after dissociation of
beled E. coli PLA2 assay was 3.8  0.4 M and 2.0  capsids or by heat shock, but not that of bee venom0.3 M for B19 and PPV PLA2, respectively. The IC50 for PLA2, was significantly reduced by polyclonal antibodiesOP was 	20 M for B19 and 11.1  0.9 M for PPV
raised against PPV VP1up (Figure 2D), demonstratingPLA2. The pH optimum of PPV PLA2 in the mixed micelles that under specific conditions virion-associated PLA2assay was 8.0 (Figure 2C). The Ca2 concentration for
activity can be revealed.optimum activity of this expressed PPV PLA2 was slightly
above 10 mM (Figure 2C), as for most sPLA2, whereas
Site-Directed Mutagenesis of Critical Amino Acidschelating Ca2 by EDTA or EGTA abolished activity of
in the Phospholipase A2 Domain and Effectboth PPV and B19 pvPLA2 (Figure 2A).
on Enzyme Activity and Viral InfectivityPPV and B19 pvPLA2 did not exhibit a substantial
The 3D structure of many group I/II and group III sPLA2ssubstrate preference among phosphatidylcholine, -eth-
has been solved (e.g., Dijkstra et al., 1981; Renetsederanolamine, and -inositol phospholipids when deter-
mined by the mixed micelles assay (Figure 2C). Since et al., 1985; Dennis, 1997; Sekar and Sundaralingam,
Novel Viral Phospholipase A2 Needed for Infection
295
Table 1. Impact of Mutations in pvPLA2 of PPV on Enzyme Activity and Infectivity
pvPLA2 Mutants (PPV) Position in Group I/II Position in Group III Relative Specific Activity (%) Relative Specific Infectivity (%)
wt — — 100 100
P21L 31 11 7.5 0.62
P21R 31 11 0.07 0.0012
P21W 31 11 4.1 0.055
D35E 42 28 0.27 0.071
D35N 42 28 0.02 0.0019
H41A 48 35 0.007 0.0011
D42N 49 36 0.04 0.0012
HD41/42AN 48/49 35/36 0.005 0.0011
D63A 99 64 0.003 0.0003
D63N 99 64 0.05 0.0007
K88R — 85 0.01 0.0035
Hydrolysis of the substrate was measured, as shown in Figure 2, with a PhosphorImager. The specific activity of mutant enzymes were
compared to that of wt PPV pvPLA2. The infectivity of wild-type (wt) and mutant viruses was measured by the number of full particles, as
established by genome equivalents in the quantitative PCR (MIMIC) assay, required to obtain one fluorescent focus upon infection, after
comparing to wt. Dilutions were used that gave at least 25 fluorescent focus units (ffu) (relative error  0.2). For wt PPV, 232 full particles
were required per fluorescent focus. The relative specific infectivity of mutants is as compared to wt results (five independent assays). The
correlation coefficient between the enzyme activity and viral infectivity, r2, was 0.898 (excluding K88R, which may be outside the PLA2 domain).
1999) and served to predict the B19/PPV pvPLA2 struc- polymerase (Tattersall and Cotmore, 1990). Therefore,
pvPLA2 is implicated in the infection process prior to theture (Figure 3). Potentially critical amino acids could thus
be targeted for site-directed mutagenesis (Weiner et al., presence of single-stranded genomes in the nucleus.
To test the hypothesis that pvPLA2 acts on entry into1994) at positions indicated in Figure 3. Transfection of
susceptible cell lines by the infectious clone of PPV the cell, wt, P21pvW, and HD41pv/42pvAN mutants of PPV
were labeled with [35S]methionine and the relative effi-yields wild-type (wt) virus (Bergeron et al., 1996). Site-
directed mutagenesis of the infectious clone prior to ciency of binding and entry was determined. Binding
and entry assays showed that pvPLA2 mutations did nottransfection enabled us to obtain defined mutant vi-
ruses. These defined mutations made it possible to influence infectivity at these stages (Figures 4A and 4B).
After entry into the cells, both wt and mutant virusesstudy the relationship between pvPLA2 activity and virus
infectivity. accumulated within perinuclear vesicular structures as
early as 2 hr after infection. Colocalization of internalizedBoth enzyme activity and viral infectivity decreased
dramatically when amino acids in the catalytic site (H41pv virus with the major lysosomal glycoprotein, LAMP-2,
was quite extensive (Figure 5A) and identified the endo-and D42pv) were mutated (Table 1). (Positions in pvPLA2
are those of PPV VP1 and are distinguished from sPLA2 cytic organelle to which PPV is delivered as a late endo-
some or lysosome (Griffiths et al., 1988; Geuze et al.,positions by adding the superscript pv.) D63pv was con-
served in pvPLA2 suggesting that it corresponded to the 1988). The extent of colocalization of mutants with
LAMP-2 was similar to that of wt (Figure 5A). PPV cap-catalytic D99 in sPLA2 (Figure 1). Its replacement by
A63pv or N63pv decreased strongly both enzyme activity sids, expressed in the baculovirus system and lacking
VP1up altogether, also colocalized with this marker andand viral infectivity, supporting the predicted relative
position of  helices in the 3D-structural model (Figure indicated that pvPLA2 is not required for traffic of PPV
to the late endosome/lysosome (Figure 5A). Incoming3). Site-directed mutagenesis of D35pv, conserved
among both sPLA2 and pvPLA2, to D35pvE and D35pvN, capsids of both wt and mutant viruses remained in the
late endosomal/lysosomal compartments and egress ofalso strongly reduced enzyme activity and infectivity
(Table 1). P21pv was conserved in the Ca2 binding loop viral capsids to the cytoplasm was not observed.
Inhibitors of sPLA2, tetracaine, and OP were used toof all pvPLA2 but not among that of sPLA2. When P21pv
was mutated to amino acids that occur often at that confirm that PLA2 activity controls viral infectivity by
facilitating lysosome-to-nucleus transport of the viralposition in sPLA2 (R, W, L), both the enzyme activity and
the infectivity were significantly reduced (Table 1). The DNA. In order to reduce the infectivity at 20 hr to 50%,
as measured by the number of fluorescent foci, the re-role of the K88pv, which is conserved in parvoviruses
and bee venom PLA2, is unknown but essential as even quired concentration was 34.6  2.8 M for tetracain
and 13  2.1 M for OP. Nuclear delivery of the viralconservative mutagenesis (K88pvR) strongly lowered ac-
tivity. Overall, the impact of mutations showed a correla- genome was essentially blocked at 12 hr and signifi-
cantly reduced at 16 hr postinfection, demonstratingtion (r2  0.898) between enzyme activity and viral in-
fectivity of the viral mutants (Table 1). that PLA2 activity is required for PPV infectivity (Figure
4D). In the presence of PLA2 inhibitors, wt virus was
predominantly localized to the late endosome/lysosomeViral Phospholipase A2 Is Required for Infection
As described above, both wt and PLA2 mutant infectious compartment (data not shown). Thus, studies with both
PLA2 mutants and PLA2 inhibitors demonstrated thatclones were effective in producing virions upon trans-
fection. Hence, pvPLA2 is required before replication PLA2 activity is required by the viral genome for its trans-
fer from the late endosomal/lysosomal compartment toand packaging. Conversion of single-stranded parvo-
viral genomes into double-stranded DNA during nor- the nucleus.
To establish whether infectious DNA and activemal infection is achieved in the nucleus by cellular DNA
Developmental Cell
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Figure 4. Parvoviruses Did Not Require
pvPLA2 Activity for Binding to the Cell Surface
or Initial Stages of Entry
(A and B) Binding (A) and entry (B) of 35S-
labeled PPV were studied using 4  105 cells
and 5  109 wt particles and equivalent
amounts of mutant viruses for binding and
twice as many for entry (experiments in qua-
druplicates). Viruses bound either to cells or
entered into cells were measured by a liquid
scintillation method after performing the
washing or antibody-stripping procedures,
respectively. pvPLA2 mutations had no effect
on virus binding to the cells or entry. Both
binding and entry of virus were time and dose
dependent (data not shown).
(C) 35S-labeled PPV particles (106 cpm) (wt
and mutants) were added to 2  107 cells in
petri dishes, and about 20% was recovered
in the cells. After cellular frationation, the dis-
tribution of virus over cytosolic and nuclear
fractions was measured by liquid scintillation.
The relative radioactivity is calculated by the
following: (nuclear fraction-bound activity)/
(cellular fraction-bound activity). Standard er-
rors are calculated from three experiments.
Few or no capsids penetrated the nucleus,
despite the large amount of virus that entered
the cells.
(D) sPLA2 inhibitors tetracain (TC), at 10 M,
and oleyloxyethylphosphorylcholine (OP), at
20 M, also reduced the number of nuclei
with viral DNA, as detected by in situ DNA
hybridization.
pvPLA2 needed to reside in the same particle to be stages of infection, without interference of newly synthe-
infectious, complementation studies were undertaken. sized PPV protein, PPV infection was performed under
The addition during infection of 1 M expressed wt conditions where protein synthesis was blocked. In the
pvPLA2 or 0.4 M snake or bee venom sPLA2 in trans, presence of cycloheximide, at 10 g/ml, incoming virus
at a 104-fold excess to PLA2 virus mutants, could not particles were not detected in the nucleus (data not
rescue the virus (data not shown). Wt virus with -propio- shown). The inability of incoming wt and mutant viral
lactone-inactivated DNA (infectivity decreased	100,000- capsids to access the nucleus was confirmed by the
fold), but active pvPLA2 (70% activity of untreated) in a lack of traffic of 35S-labeled capsids to the nucleus. In
10-fold excess, also failed to rescue mutant virus upon this experiment, about 106 cpm of labeled virus (wt,
coinfection. Active pvPLA2 and infectious DNA is there- P21pvW, and HD/AN mutants) were added, and the im-
fore required in cis to obtain infection. port of radiolabel into the nuclear fraction was assessed
at 1 and 16 hr after infection. While 2  105 cpm of
labeled virus entered the cells, the amount of cpm inRole of Viral Phospholipase A2 during Infection
the nuclear fraction remained constant over this periodA critical role for viral delivery to the late endosome/
at0.5% (Figure 4C), essentially equivalent to the extentlysosome in viral infectivity was demonstrated by the
of cytosolic contamination of the nuclear fraction asfact that adding the lysosomotropic base NH4Cl prior to
measured by lactate dehydrogenase activity (0.5%).infection reduced viral infection in a dose-dependent
Relative to the large quantity of virus that entered thefashion (5, 20, and 50 mM decreased PPV infectivity by
cells, little or no virus-associated protein penetrated the82%, 99% and 99.92%, respectively) and also exacer-
nucleus.bated the effect of the mutations by delaying infectivity
In situ DNA hybridization was undertaken to investi-and lowering the number of fluorescent foci even further
gate whether mutant viruses transferred their genome(Figure 5B).
from the late endosomal/lysosomal compartment to theDe novo viral antigen was detected in the nucleus by
nucleus as efficiently as wt PPV. At 4 and 8 hr, viralimmunofluorescence from about 8–12 hr postinfection
DNA was detected in the perinuclear late endosomal/with wt PPV (Figure 5B) but only after at least 18 hr and
lysosomal compartments, whereas wt viral DNA replica-in far fewer nuclei for mutant virus (Figure 5B; Table 1).
In order to selectively follow incoming wt virus at late tion started in the nucleus prior to 12 hr postinfection
Novel Viral Phospholipase A2 Needed for Infection
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Figure 5. Incoming PPV Capsids Target Late
Endosomes/Lysosomes
(A) Colocalization of PPV and LAMP-2 was
studied by confocal microscopy. Anti-PPV
antibodies were labeled with FITC, giving
green fluorescence, and anti-LAMP-2 anti-
bodies with Texas red, giving red fluores-
cence. Colocalization of PPV and LAMP-2 re-
sulted in yellow staining. Both wt and mutants
as well as capsids lacking PLA2 showed ex-
tensive colocalization with LAMP-2 in the late
endosomes/lysosomes.
(B) Immunofluorescence (anti-PPV antibod-
ies) was used to follow the entry and infection
of PT cells by wt or mutant virus (concentra-
tion of 0.5 g/ml), with or without 20 mM
NH4Cl. After 12 hr, both P21W mutant virus
and wt virus in the presence of NH4Cl were
perinuclear. In the absence of NH4Cl, wt virus
infected many cells as indicated by the pres-
ence of positive nuclei. This was the result of
synthesis of new capsid proteins, as in the
presence of cycloheximide (10g/ml) no pos-
itive nuclei were observed (data not shown).
After 18 hr, few positive nuclei were detected
with the P21W mutant or with wt virus in the
presence of NH4Cl.
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Figure 6. Distribution of Viral DNA in Infected
Cells
Using in situ hybridization, incoming viral
DNA was detected in the cytoplasm after 4
(data not shown) and 8 (A) hr, whereas repli-
cating viral DNA was found at 12 hr postinfec-
tion (B). At this stage, viral DNA could not be
detected in the nucleus in the case of the HD/
AN mutant, lacking pvPLA2 activity (C), or with
the P21pvW mutant, which has weak PLA2 ac-
tivity (D).
(Figures 6A and 6B). The inability to detect DNA of the (Figure 3). This deficiency may be compensated for by
other structures in the viral capsid and sequences out-HD and P21 mutants at the same time in the nucleus
(Figures 6C and 6D) suggested that DNA from mutant side the conserved PLA2 domain. The increased enzyme
activity obtained after expression of extended PLA2 do-virus did not penetrate the nucleus, since incoming viral
DNA would be replicated rapidly to detectable amounts mains supports this hypothesis and also corroborates
the proposed structural resemblance of the pvPLA2 withby the host cell machinery. In conclusion, PLA2 mutants
are strongly impaired in the transfer of the viral genome those from group III (Figure 3). The N-terminal helix in
group I/II/V/X sPLA2s is upstream of the Ca2 bindingfrom the perinuclear vesicles into the nucleus.
loop and binds to the interface (Gelb et al., 1999). How-
ever, this helix is predicted to be downstream of theDiscussion
catalytic site in pvPLA2, as in group III sPLA2. This projec-
tion by molecular modeling is supported by (1) the minorThe pvPLA2s Are a Subgroup
impact on enzyme activity caused by a truncation up-in the PLA2 Superfamily
stream of the Ca2 binding loop and (2) the absence ofThe conserved VP1up domain of parvoviruses is shown
extra sequences upstream of the Ca2 binding loop inhere to exhibit a PLA2 activity that is essential for parvo-
some parvoviruses (immunosuppressive MVM, BmDNV;virus infectivity. pvPLA2s and sPLA2s share a conserved
Figure 1).Ca2 binding loop and catalytic site. The pvPLA2s differ
In sPLA2, H48 functions as a general base and is as-from sPLA2s as follows: (1) cysteine is absent from all
sisted by D99 to deprotonate a catalytic water moleculeVP1up pvPLA2 sequences, whereas all sPLA2s are disul-
that hydrolyzes the phospholipid ester (Dennis, 1997).fide-rich; (2) the connecting sequence between the two
The adjacent D49, via its -carboxyl group, and back-helices containing the catalytic site (D63pv and H41pv) is
bone carbonyl oxygens from Y28, G30, and G32 in themuch shorter in pvPLA2 than in sPLA2 (D99 and H48);
Ca2 binding loop coordinate the catalytic Ca2 cofactorand (3) P21pv in the YXGPG sequence in the Ca2 binding
involved in the stabilization of the transition state (Den-loop of all pvPLA2 is strictly conserved, in contrast to
nis, 1997; Murakami et al., 1997; Dessen, 2000). Thethat of sPLA2. In view of the differences with sPLA2,
observation that D35pv/D42 is strongly conserved amongsuch as structure (Figure 3), biological role, and unique
all pv/sPLA2 indicated that this residue has an essentialsequences (Figure 1), we propose that pvPLA2s form a
role. Mutation of this residue was poorly tolerated (Tablenew group within the PLA2 superfamily, which we refer
1). The 3D structures suggest that D35pv/D42 is criticalto as group XIII.
for the positioning of the Ca2 binding loop, with respectMolecular modeling of pvPLA2 suggests that the
to the active site, by three hydrogen bonds.shorter loop connecting the H41pv and D63pv helices can-
The catalytic efficiencies of pvPLA2s, as expressednot shield the catalytic D63pv from the aqueous phase
as the -wing does with D99 of the group I/II/V/X sPLA2s by (kcat/KM)app, were within the 1–2 log range of that of
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bee venom PLA2. These differences may be due to the transfer. The acidic lysosomal milieu may facilitate con-
formational changes of the viral capsid and consequentassay system or the cloning of incomplete active do-
mains for expression but could also reflect real differ- externalization of the VP1up. Shielding of small amounts
of externalized pvPLA2 from the acidic lumen, perhapsences. Large activity differences are common among
sPLA2s and have been attributed to variations in strength via membrane interaction, may enable pvPLA2 activity
and viral egress. Expression of active PLA2 by a smallof the interfacial contacts with the substrate (Han et al.,
1999). The high catalytic efficiency of PPV PLA2 may be subset of virions could explain the apparent inefficiency
of lysosome-to-nucleus delivery and viral infectivity de-due to a prolonged stay at the interface and to a scooting
mode of hydrolysis. scribed here.
In situ hybridization studies showed that pvPLA2 mu-
tations as well as inhibition of PLA2 activity affected thepvPLA2 Activity Is Required for Viral Infection
transfer of the viral genome to the nucleus. IncomingThe correlation between enzyme activity and virus in-
mutant as well as wt virus capsids accumulate in perinu-fectivity underscores the essential role of this enzyme
clear lysosomal compartment over extended time peri-during infection. Data obtained with transfection of wt
ods. In contrast, incoming AAV particles can be detectedor mutant infectious clones established that vPLA2 acts
in the nucleus from about 3 hr postinfection (Sanliogluprior to viral replication and expression. Little is known
et al., 2000). VP1up of AAV is large and probably local-about mechanisms underlying the early steps of parvovi-
ized on the outside of the particle, like that of GmDNVrus infection. The demonstrated delivery of PPV to
and B19 (Rosenfeld et al., 1992), and thus may not re-LAMP-2 positive late endosomes/lysosomes confirms
quire this VP1up externalization step, leading to a differ-that PPV enters the cell via the classical endocytic path-
ent genome delivery mechanism via intact particles.way, consistent with other parvoviruses (Vihinen-Ranta
The outside location of B19-VP1up (Rosenfeld et al.,et al., 1998; Duan et al., 1999; Parker and Parrish, 2000).
1992) and its phospholipase domain could explain theColocalization studies with LAMP-2, using confocal mi-
presence of antiphospholipid-protein complex antibod-croscopy, showed that both wt and mutant viruses are
ies in B19-related syndromes such as SLE (Loizou etrapidly delivered to the late endosome/lysosome, by
al., 1997), and the specific expression of B19 VP1 in theabout 2–4 hr, and that incoming capsids remained in this
synovia of RA patients (Takahashi et al., 1998b) couldlocation. Capsids that lack VP1up, and consequently
contribute to the high PLA2 activity in the synovial fluid.pvPLA2, also reached these perinuclear organelles and
The requirement of pvPLA2 for virus infectivity and thecould not be distinguished from wt. Therefore, pvPLA2
differences between pvPLA2 and sPLA2 sequence pro-is not required for attachment to the cell surface, early
files make this viral enzyme an obvious target for design-stages of endocytosis, or the transfer of virus to late
ing a new class of specific antiviral drugs that act viaendosomes.
pvPLA2 inhibition.The position of VP1up inside the capsid prior to endo-
cytosis was confirmed in this study for PPV as pvPLA2
Experimental Procedureswas detected in dissociated capsids but hardly in intact
capsids. Moreover, antibodies to VP1up do not bind to Vectors, Infectious Clones, and Site-Directed Mutagenesis
virus in ELISA assays (data not shown). The cis require- The pN2 infectious clone of PPV was derived from the pPPV2/17
ment of pvPLA2 for productive infection and comple- clone (pUC19 with the genome of PPV NADL-2 inserted in its SmaI
site; Bergeron et al., 1993) by deletion of a vector fragment frommentation studies showing that wt pvPLA2 cannot res-
2617 via 2686/0 to 410 (KpnI) to render several restriction sites incue PLA2-negative mutants also demonstrate the critical
the PPV insertion unique. Mutants of this clone were obtained byrole of pvPLA2 in viral infectivity. To implement its critical site-directed mutagenesis (Weiner et al., 1994) of the pVPi clone
role during entry, PLA2 should gain access to the cellular (pBluescriptIISK, containing PPV sequence 2287–3664) and then
environment. Externalization of VP1up from intact parti- replacing the KasI-EcoRI fragment in pN2 by the corresponding
cles can be achieved in vitro (Cotmore et al., 1999) but fragment from pVPi. For expression studies, the pBADTBX vector
was constructed from the pBAD/TOPO Thiofusion expression vectoris accompanied by a conformational transition so that
(Invitrogen) by inserting downstream of the thioredoxin gene a TEVthe viral genome becomes susceptible to externally ap-
protease site followed by a polylinker (BglII, EcoRI, SfuI, XhoI, SstI,plied DNase. Treatment of MVM parvovirus with extracts
XbaI). The vector contains the sequence for a His-tag downstream
from susceptible cells, but not from nonsusceptible of this sequence.
cells, also rendered the viral genome accessible to
DNase (Previsani et al., 1997). This suggests that sus- Preparation of Virus and Transfection with Infectious Clones
The PT cell line (Bergeron et al., 1996) was used for all PPV infectionceptible cells contain a factor that destabilizes the virion
experiments and was maintained in Dulbecco’s modified Eagle’sand may be required for the externalization of VP1up.
medium (DMEM) supplemented with penicillin (100 IU/ml), strepto-The absence of disulfide bridges in pvPLA2, in contrast
mycin (50 g/ml), and 8% fetal calf serum (HyClone). Semiconfluentto all known sPLA2, would facilitate this externalization monolayers were used for infection. For wild-type (wt) virus, cyto-
through the cylindrical channel at the 5-fold axis of the pathic effects were observed 3–5 days after infection. Virus was
capsid. In contrast to the loop 3 and 4 polypeptide collected from the medium by ultracentrifugation and the pellet was
redissolved in a small volume of PBS. After a DNase and trypsinchains around the 3-fold axis, the subunits are not inter-
treatment, the virus was further purified by differential centrifugationwoven at the 5-fold axis and the capsid may open further
followed by sucrose gradient centrifugation. For transfection, thearound the 5-fold cylinder during this process. External-
undigested pN2 clone or its mutants were introduced into PT cellsization would expose the pvPLA2 group only when es- to obtain virus using the Lipofectamine-plus kit (GIBCO-BRL) ac-
sential, together with other VP1up functions (DNA bind- cording to the supplier’s recommendations. For mutant clones, two
ing, nuclear localization) that may be required in a additional infection passages served to monitor for possible re-
vertants.coordinated fashion for endosome exit and viral genome
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Preparation of PPV Recombinant Capsids monoclonal antibody (ATCC CRL-1745) was used. Virus was diluted
so that at least 25 ffu were counted and the relative error in theTo produce viral capsids without VP1up, the PPV VP2 coding region
estimates of ffu/ml would be 0.2.(2810–4549) was cloned into BamHI-XbaI sites of the pFastbac ba-
The double labeling of internalized PPV with LAMP-2 was per-culovirus transfer vector and recombinant baculovirus was gener-
formed using a porcine polyclonal anti-PPV antibody and the AC17ated according to the supplier’s recommendations (GIBCO-BRL).
mouse anti-canine LAMP-2 monoclonal antibody (Nabi et al., 1991;High Five cells (InVitrogen) were infected with 5 MOI of VP2-express-
Nabi and Rodriguez-Boulan, 1993) that has previously been reporteding recombinant baculovirus and harvested after 72 hr. Cells were
to recognize mink LAMP-2 (Hariri et al., 2000). Appropriate controlslysed with 1% trypsin, and the lysate was concentrated and washed
were performed to ensure that the antibody labeling was specific.twice with one vol 0.1 M NaHCO3 (pH 8.6) in Centricon plus-80 filters
In situ hybridization was performed using DIG-conjugated anti-VP1(100,000 MW cutoff). Concentrated recombinant VP2 capsids were
and anti-NS1 probes and FITC-conjugated anti-DIG antibody sand-then purified by centrifugation on two successive 20% sucrose gra-
wich labeling according to the manufacturer’s instructions (Rochedients and on a CsCl gradient and dialyzed.
Molecular Biochemicals). Nuclear labeling was performed by the
addition of 0.02 mg/ml propidium iodide to paraformaldehyde-fixedPhospholipase A2 Expression and Activity
cells after labeling. Confocal images were acquired using the 63The following VP1up domains were cloned in expression vectors:
PlanApochromat objective of a Leica TCS SP confocal microscopePPV-VP1up amino acid 2–174, B19-VP1up amino acid 2–240,
equipped with argon and krypton laser sources.GmDNV-VP1up amino acid 1–378. VP1up was amplified by PCR
using primers containing the BglII and XbaI restriction sites, respec-
Effect of Viral Phospholipase A2 Mutations during Bindingtively. The amplicons were cloned into BglII-XbaI of the pBADTBX
or Entry into the Cellsvector, and the clones were sequenced. Correct clones were then
The binding of virus to cells was measured by scintillation countingused to transform E. coli BL21-CodonPlus(DE3)-RIL (Stratagene) to
after adsorption of 35S-labeled particles to the cells at 4
C and wash-obtain a fusion protein. This protein was purified on a Ni-agarose
ing. In detail, metabolic labeling of virus with 35S was achieved as
column. SDS-PAGE and Coomassie blue staining revealed a single
follows: wt pN2 as well as its P21W and HD mutants were transfected
band. This protein could be cleaved by TEV protease to remove the
into PT cells in 6-well plates (1 g DNA/well) using the Lipofectam-
thioredoxin. PLA2 activity of the protein was not significantly affected ine-plus kit (GIBCO-BRL). The medium was changed after 12 hr to
by the presence of thioredoxin. PLA2 activity of expressed VP1up methionine-free medium. After an additional hour, [35S]methionine
was established using the mixed micelles assay (Manjunath et al., (60 Ci/ml) was added in fresh methionine-free medium to the cells.
1994) or the E. coli radioactive assay (Elsbach and Weiss, 1991). After a further 12 hr incubation period, 2 ml regular medium (8%
For the mixed micelles assay, the substrates (from New England fetal bovine serum [FBS] in DMEM) was added to the cells and virus
Nuclear/DuPont) were 6M L-3-phosphatidylcholine,1,2-di[1-14C]ol- was purified 60 hr after transfection. Binding to cells was measured
eoyl (specific activity 110 mCi/mmol), L-3-phosphatidylinositol L-1- as follows: about 104 cpm [35S]methionine-labeled viral particles in
stearoyl-2-[1-14C]arachidonyl (specific activity 48 mCi/mmol), or 0.4 ml regular medium were added to PT cells grown in 24-well
phosphatidylethanolamine L-1-palmitoyl,2-[1-14C]arachidonyl (spe- plates. After 5 hr of incubation at 4
C, the cells were washed 3 times
cific activity 54.6 mCi/mmol), and the assay was modified in the with ice-cold DMEM containing 1% FBS, scraped from the dish,
following way: 1 mM Triton X-100 was used instead of deoxycholate; and washed once more by centrifugation. Cells were collected in
the reaction total volume was 50 l and was stopped after 10 min 100l medium, and the radioactivity was measured in 5 ml EcoLite
by adding 80 l chloroform/methanol (2:1) and 50 l of saturated scintillation fluid (ICI). For entry, both wt and mutant viruses (4 plus
KCl solution. Separation was on silica gel thin-layer chromatography 4 wells of each, on separate 24-well plates) were adsorbed to the
plates. Optimal separation of the phosphatidylcholine reaction prod- cells at 4
C for 5 hr. Later, the cells were washed twice with ice-
ucts was obtained using a solvent solution containing chloroform, cold DMEM containing 1% FBS before incubating 4 wells of each
methanol, and water (65:35:4). For phosphatidylethanolamine and for 1, 3, 4 (at three different virus concentrations) and 5 hr at 37
C
phosphatidylinositol, chloroform and methanol (87:13) were used as and 4 wells at 4
C, respectively. After the incubation, the cells were
solvent. The separated products were quantified using a Molecular washed twice with DMEM containing 5 times-diluted porcine poly-
Dynamics PhosphorImager SI after drying. Bee venom PLA2 was clonal anti-PPV antibody and 1% FBS and at last with DMEM con-
purchased from Sigma-Aldrich (cat. no P9279) at 1360 U/mg. Only taining 1% FBS at a pH of 8.5. The difference in cpm associated
with the cells between the 37
C samples and 4
C (controls) afterthe regression lines of activity versus dilution with a correlation
stripping with antibody accounted for the entry (error bars sum ofcoefficient r2 	 0.98 were used to calculate the amount of protein
those obtained at 4
C and 37
C). For entry into the nucleus 106 cpmto hydrolyze 50% of the substrate in the mixed micelles assay.
[35S]methionine-labeled viral particles in 5 ml regular medium wereAlternatively, the first-order rate constant, k, was determined from
added to PT cells grown in 10 cm petri dishes. After 5 hr of incubationreaction progress curves using an integrated first-order rate equa-
at at 4
C, the cells were washed once with regular medium andtion ([P] S0(1 ekt) (P is product and S is substrate concentration)
incubated at 37
C either for 1 or 16 hr. Cells were washed once within which k  (kcat/KM)appE0 and E0 the total enzyme concentration.
PBS and scraped from the dishes. Nuclear fraction purification was
performed by a cellular fractionation method, based on plasmaPhospholipase Activity in Virions
membrane lysis (Sperinde and Nugent, 1998). Less than 0.5% cyto-Activity was determined with purified virus prior to and after dissoci-
plasmic contamination was found in the nuclear fraction in threeation of the capsids or a heat shock. For dissociation of capsids,
separate fractionation procedures measuring the lactate dehydro-
virus in 50 mM Tris-HCl buffer, pH 8.0, was treated by adding NaOH
genase (LDH) activity by the Cytotoxicity Detection Kit (Roche Mo-
to 0.05 N and, after 5 min at room temperature, neutralized with 0.1
lecular Biochemicals). Integrity of the purified nuclei was confirmed
N HCl. Heat shock was 2 min at 70
C followed by gradual cooling.
by fluorescent microscopy after staining the nuclei with Hoechst
33258. Radioactivity of each cellular fraction was quantitated by
MIMIC PCR, Immunofluorescence, and In Situ Hybridization counting in a liquid scintillation analyzer.
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